Personalised gene therapy helps teenager with severe epilepsy walk independently
Researchers at the University of California San Diego have reported encouraging results from a highly personalised gene therapy developed for a teenager living with a rare genetic form of severe epilepsy. Following treatment, the patient experienced significant neurological improvements, including the ability to walk independently after previously requiring substantial mobility support. The therapy was specifically designed to target the patient's individual genetic mutation, demonstrating the growing feasibility of developing bespoke genetic medicines for ultra-rare diseases where conventional drug development approaches are often not viable.
This case represents another important milestone in the emergence of personalised genetic medicine. Advances in gene sequencing, vector engineering and precision manufacturing are increasingly enabling therapies tailored to individual patients rather than broader disease populations.
Read more via UC San Diego Today
Lyora Therapeutics launches to advance next-generation genetic medicines for inherited retinal diseases
Lyora Therapeutics has launched with seed funding to advance a pipeline of genetic medicines targeting inherited retinal diseases. The company is focused on developing therapies based on biologically validated targets, with the goal of addressing the underlying genetic causes of vision loss through precision genetic medicine. The funding will support the continued development of Lyora's early-stage pipeline as it works towards clinical translation, adding another specialist company to the growing ophthalmic gene therapy landscape.
Inherited retinal diseases remain one of the most active areas of gene therapy development, supported by strong scientific validation and continued clinical progress. Lyora's launch demonstrates that investors remain willing to support early-stage companies with differentiated science and clearly defined therapeutic strategies, even as funding becomes increasingly selective.
Read more via Globe Newswire
Repligen to acquire BioLife Solutions in $1.5 billion deal
Repligen has announced plans to acquire BioLife Solutions in a deal worth approximately $1.5 billion, bringing together two of the sectors leading manufacturing technologies for cell and gene therapies. The acquisition combines Repligen’s expertise in bioprocessing with BioLife’s portfolio of cell preservation media, cryopreservation technologies and cell processing tools, creating a more comprehensive offering across the advanced therapy manufacturing workflow.
BioLife's technologies are already widely used throughout the industry, supporting a significant proportion of approved cell therapies and late-stage clinical programmes. By integrating these capabilities, Repligen aims to strengthen its position as demand grows for scalable, end-to-end manufacturing solutions that can support therapies from early development through commercial production.
As more advanced therapies move towards commercialisation, manufacturing has become a key differentiator. This acquisition reflects increasing confidence in the long-term growth of the sector and highlights the ongoing consolidation of life science tools companies seeking to provide integrated manufacturing ecosystems. For therapy developers, access to more connected manufacturing solutions could help improve efficiency, reduce operational complexity and accelerate commercial readiness.
Read more via PharmaPhorum
)